Canada · Delayed Price · Currency is CAD BioRem Statistics
Total Valuation
BioRem has a market cap or net worth of CAD 49.30 million. The enterprise value is 41.96 million.
| Market Cap | 49.30M |
| Enterprise Value | 41.96M |
Important Dates
The next estimated earnings date is Monday, August 24, 2026.
| Earnings Date | Aug 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioRem has 16.22 million shares outstanding. The number of shares has decreased by -1.39% in one year.
| Current Share Class | 16.22M |
| Shares Outstanding | 16.22M |
| Shares Change (YoY) | -1.39% |
| Shares Change (QoQ) | +9.40% |
| Owned by Insiders (%) | 1.99% |
| Owned by Institutions (%) | n/a |
| Float | 15.89M |
Valuation Ratios
The trailing PE ratio is 11.27.
| PE Ratio | 11.27 |
| Forward PE | n/a |
| PS Ratio | 1.11 |
| PB Ratio | 3.22 |
| P/TBV Ratio | 3.22 |
| P/FCF Ratio | 38.94 |
| P/OCF Ratio | 27.17 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.90, with an EV/FCF ratio of 33.15.
| EV / Earnings | 8.42 |
| EV / Sales | 0.94 |
| EV / EBITDA | 5.90 |
| EV / EBIT | 6.28 |
| EV / FCF | 33.15 |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.02 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.37 |
| Debt / FCF | 2.09 |
| Interest Coverage | 43.44 |
Financial Efficiency
Return on equity (ROE) is 38.33% and return on invested capital (ROIC) is 71.57%.
| Return on Equity (ROE) | 38.33% |
| Return on Assets (ROA) | 14.00% |
| Return on Invested Capital (ROIC) | 71.57% |
| Return on Capital Employed (ROCE) | 38.75% |
| Weighted Average Cost of Capital (WACC) | 8.80% |
| Revenue Per Employee | 1.31M |
| Profits Per Employee | 146,493 |
| Employee Count | 34 |
| Asset Turnover | 1.49 |
| Inventory Turnover | 11.14 |
Taxes
In the past 12 months, BioRem has paid 1.57 million in taxes.
| Income Tax | 1.57M |
| Effective Tax Rate | 23.96% |
Stock Price Statistics
The stock price has increased by +56.70% in the last 52 weeks. The beta is 0.87, so BioRem's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +56.70% |
| 50-Day Moving Average | 3.02 |
| 200-Day Moving Average | 2.52 |
| Relative Strength Index (RSI) | 44.54 |
| Average Volume (20 Days) | 33,670 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioRem had revenue of CAD 44.44 million and earned 4.98 million in profits. Earnings per share was 0.27.
| Revenue | 44.44M |
| Gross Profit | 13.05M |
| Operating Income | 6.69M |
| Pretax Income | 6.55M |
| Net Income | 4.98M |
| EBITDA | 6.98M |
| EBIT | 6.69M |
| Earnings Per Share (EPS) | 0.27 |
Balance Sheet
The company has 9.99 million in cash and 2.65 million in debt, with a net cash position of 7.34 million or 0.45 per share.
| Cash & Cash Equivalents | 9.99M |
| Total Debt | 2.65M |
| Net Cash | 7.34M |
| Net Cash Per Share | 0.45 |
| Equity (Book Value) | 15.30M |
| Book Value Per Share | 0.95 |
| Working Capital | 14.51M |
Cash Flow
In the last 12 months, operating cash flow was 1.81 million and capital expenditures -548,337, giving a free cash flow of 1.27 million.
| Operating Cash Flow | 1.81M |
| Capital Expenditures | -548,337 |
| Depreciation & Amortization | 291,191 |
| Net Borrowing | -661,802 |
| Free Cash Flow | 1.27M |
| FCF Per Share | 0.08 |
Margins
Gross margin is 29.36%, with operating and profit margins of 15.05% and 11.21%.
| Gross Margin | 29.36% |
| Operating Margin | 15.05% |
| Pretax Margin | 14.74% |
| Profit Margin | 11.21% |
| EBITDA Margin | 15.70% |
| EBIT Margin | 15.05% |
| FCF Margin | 2.85% |
Dividends & Yields
BioRem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.39% |
| Shareholder Yield | 1.39% |
| Earnings Yield | 10.10% |
| FCF Yield | 2.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRem has an Altman Z-Score of 4.26 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.26 |
| Piotroski F-Score | 7 |